Clin2Atlas
AtlasOther conditionsHemoglobinopathies and hemolytic anemias

Sickle cell disorders

3Curable in someAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020251999 — Deferiprone approved (FDA)2004 — Glutamine approved (FDA)2019 — Voxelotor approved (FDA)2019 — Crizanlizumab approved (FDA)2023 — Lovotibeglogene autotemcel approved (FDA)2023 — Exagamglogene autotemcel approved (FDA)
1999: Drug approval — Deferiprone approved (FDA). 2004: Drug approval — Glutamine approved (FDA). 2019: Drug approval — Voxelotor approved (FDA). 2019: Drug approval — Crizanlizumab approved (FDA). 2023: Drug approval — Lovotibeglogene autotemcel approved (FDA). 2023: Drug approval — Exagamglogene autotemcel approved (FDA)

What's being tested now

2002: 1 trials started2004: 1 trials started2007: 2 trials started2008: 1 trials started2010: 1 trials started2011: 1 trials started2012: 1 trials started2013: 1 trials started2014: 6 trials started2015: 1 trials started2016: 3 trials started2017: 6 trials started2018: 7 trials started2019: 8 trials started2020: 15 trials started2021: 11 trials started2022: 17 trials started2023: 20 trials started2024: 51 trials started2025: 50 trials started2026: 55 trials started20102020202655

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 236 active Acute Chest Syndrome trials on Clin2 →

Related

ThalassemiasThalassemias traitSickle cell traitG6PD deficiencyG6PD traitOther hemoglobinopathies and hemolytic anemias

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.